Terms: = Ovarian cancer AND NCOA4, RP11-481A12_4, 8031, ENSG00000138293, PTC3, ELE1, Q13772, RFG, DKFZp762E1112, ARA70
23952 results:
1. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
2. Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation.
Perri G; Vilas Boas VG; Nogueira MRS; Mello Júnior EJF; Coelho AL; Posadas EM; Hogaboam C; Cavassani KA; Campanelli AP
Cancer Immunol Immunother; 2024 Apr; 73(6):110. PubMed ID: 38662248
[TBL] [Abstract] [Full Text] [Related]
3. Exceptional lymph node recurrence of an unusual ovarian tumor 16 years later: a case report.
Sakhri S; Slimane M; Bouaziz H; Khessairi N; Boujelbene N; Ben Dhiab T
J Med Case Rep; 2024 Apr; 18(1):217. PubMed ID: 38654310
[TBL] [Abstract] [Full Text] [Related]
4. Granulosa cell tumor of the ovary: a series of 6 cases.
da Costa REAR; Silva MCA; Cavalcante ECX; Branco ROC; Dos Reis CA; Vieira SC
Pan Afr Med J; 2024; 47():58. PubMed ID: 38646138
[TBL] [Abstract] [Full Text] [Related]
5. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
6. Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.
Guo J; Zeng X; Zhu Y; Yang D; Zhao X
J Transl Med; 2024 Apr; 22(1):367. PubMed ID: 38637885
[TBL] [Abstract] [Full Text] [Related]
7. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant ovarian cancer: Final Overall Survival and Biomarker Analyses.
Konstantinopoulos PA; Cheng SC; Lee EK; da Costa AABA; Gulhan D; Wahner Hendrickson AE; Kochupurakkal B; Kolin DL; Kohn EC; Liu JF; Penson RT; Stover EH; Curtis J; Sawyer H; Polak M; Chowdhury D; D'Andrea AD; Färkkilä A; Shapiro GI; Matulonis UA
JCO Precis Oncol; 2024 Apr; 8():e2300635. PubMed ID: 38635934
[TBL] [Abstract] [Full Text] [Related]
8. Imaging for local recurrence of breast cancer.
Schlaiss T; Bott L; Herbert SL; Bartmann C; Kiesel M; Salmen J; Sauer ST; Christner SA; Petritsch B; Grunz JP; Woeckel A; Löb S; Diessner J
J Cancer Res Clin Oncol; 2024 Apr; 150(4):200. PubMed ID: 38627285
[TBL] [Abstract] [Full Text] [Related]
9. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
[TBL] [Abstract] [Full Text] [Related]
10. [Gonadoblastoma: Clinicopathological study and literature review of 3 cases].
Bao ML; Li X; Chen G; Li H; Chen W; Li HX
Zhonghua Nan Ke Xue; 2023 Jul; 29(7):634-638. PubMed ID: 38619412
[TBL] [Abstract] [Full Text] [Related]
11. Cytotoxic activity and cell specificity of a novel LHRH peptide drug conjugate, D-Cys6-LHRH vedotin, against ovarian cancer cell lines.
Vankadara S; Ke Z; Wang S; Foo SY; Gunaratne J; Lee MA; Koh X; Chia CSB
Chem Biol Drug Des; 2024 Apr; 103(4):e14516. PubMed ID: 38618710
[TBL] [Abstract] [Full Text] [Related]
12. The Clinicopathological Significance of the Cyclin D1/E1-Cyclin-Dependent Kinase (CDK2/4/6)-Retinoblastoma (RB1/pRB1) Pathway in Epithelial ovarian cancers.
Lashen A; Algethami M; Alqahtani S; Shoqafi A; Sheha A; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612869
[TBL] [Abstract] [Full Text] [Related]
13. Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine.
Elshami M; Jaber I; Alser M; Al-Slaibi I; Jabr H; Ubaiat S; Tuffaha A; Khader S; Khraishi R; Arafeh ZA; Al-Madhoun S; Alqattaa A; Yaseen A; El Hadi AA; Barhoush O; Hijazy M; Eleyan T; Alser A; Hziema AA; Shatat A; Almakhtoob F; Mohamad B; Farhat W; Abuamra Y; Mousa H; Adawi R; Musallam A; Albarqi SI; Abu-El-Noor N; Bottcher B
BMC Public Health; 2024 Apr; 24(1):1027. PubMed ID: 38609950
[TBL] [Abstract] [Full Text] [Related]
14. Construction and analysis of competitive endogenous RNA networks and prognostic models associated with ovarian cancer based on the exoRBase database.
Chen Z; Wang C; Ding J; Yu T; Li N; Ye C
PLoS One; 2024; 19(4):e0291149. PubMed ID: 38603733
[TBL] [Abstract] [Full Text] [Related]
15. Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses.
Baik SH; Baye F; McDonald CJ
Menopause; 2024 May; 31(5):363-371. PubMed ID: 38595196
[TBL] [Abstract] [Full Text] [Related]
16. Development and validation of an ultrasound-based deep learning radiomics nomogram for predicting the malignant risk of ovarian tumours.
Du Y; Xiao Y; Guo W; Yao J; Lan T; Li S; Wen H; Zhu W; He G; Zheng H; Chen H
Biomed Eng Online; 2024 Apr; 23(1):41. PubMed ID: 38594729
[TBL] [Abstract] [Full Text] [Related]
17. Olaparib Addition to Maintenance Bevacizumab Therapy in ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
[TBL] [Abstract] [Full Text] [Related]
18. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
[TBL] [Abstract] [Full Text] [Related]
19. Mitogen-Activated Protein Kinase Inhibitor-Induced Inflammatory Alopecia in Woman With ovarian cancer.
Rose L; Minta A; Plaza J; Cohn DE; Dulmage B
J Drugs Dermatol; 2024 Apr; 23(4):e102-e103. PubMed ID: 38564383
[TBL] [Abstract] [Full Text] [Related]
20. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
Yuan H; Li N; Wu L; Yao H
J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
[TBL] [Abstract] [Full Text] [Related]
[Next]